$BTAI News

BioXcel Presents New Data From Phase 3 SERENITY At-Home Trial Evaluating BXCL501 For Acute Treatment Of Agitation Associated With Bipolar Disorders Or Schizophrenia At 2026 ASCP Annual Meeting

BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates

BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

BioXcel Therapeutics, Inc. (BTAI) Expected to Beat Earnings Estimates: Should You Buy?

BioXcel Therapeutics, Inc. (BTAI) Discusses Commercial Launch Strategy and Market Opportunity for IGALMI in At-Home Setting Transcript

H.C. Wainwright Adjusts BioXcel Therapeutics, Inc. (BTAI) Outlook Following Capital Structure Concerns

BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting

How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Promise And Dilution Risks

BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions

BioXcel Therapeutics Kicks Off DoD-Funded Phase 2a Study Of BXCL501 For Acute Stress Reactions, Led By UNC Institute For Trauma Recovery

BioXcel Therapeutics Kicks Off DoD-Funded Phase 2a Study Of BXCL501 For Acute Stress Reactions, Led By UNC Institute For Trauma Recovery

HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $5

BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting

The FDA Accepts Its Bioxcel Therapeutics' Supplemental New Drug Application For Igalmi For At-home Use In The Acute Treatment Of Agitation Associated With Bipolar Disorders Or Schizophrenia, PDUFA Date Of November 14

How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Hopes And Dilution Risks

BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting

BioXcel Therapeutics Q4 EPS $(0.58) Beats $(0.69) Estimate, Sales $256.000K Beat $250.000K Estimate

Rodman & Renshaw Initiates Coverage On BioXcel Therapeutics with Buy Rating, Announces Price Target of $17

How The BioXcel Therapeutics (BTAI) Story Is Shifting With Dilution Risks And Funding Needs

BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering